Business, energy, technology, markets and global industry news from Business News Today

oncology

PharmaDeviceNews oncology
Pharma & Biotech

Can Biohaven’s BHV-1510 avoid the safety pitfalls of existing Trop2 ADCs in solid tumors?

Biohaven Ltd. presented updated Phase 1 clinical data on BHV-1510, its next-generation Trop2-targeting antibody-drug conjugate, at the 2025 European Society for Medical Oncology (ESMO) Immuno-Oncology Congress in London. The results, derived from a heavily pretreated population with advanced or metastatic solid tumors, showed encouraging response rates across non-small cell lung cancer, endometrial cancer, and urothelial

Read More
Pharma & Biotech

Atossa pivots into rare disease with FDA nod for (Z)-Endoxifen in Duchenne muscular dystrophy

Atossa Therapeutics has received Rare Pediatric Disease (RPD) designation from the U.S. Food and Drug Administration for (Z)-Endoxifen in Duchenne muscular dystrophy (DMD), a strategic shift that positions the estrogen receptor modulator for possible use in pediatric neuromuscular disorders. If approved, the program could qualify for a transferable Priority Review Voucher, but the timeline and

Read More
Pharma & Biotech

Marengo’s Invikafusp alfa shows early promise in metastatic breast cancer with dual-immunotherapy and ADC combination

Marengo Therapeutics has presented early-stage results from its STARt-002 clinical trial evaluating invikafusp alfa (Invika), a novel T cell immunotherapy candidate, in combination with sacituzumab govitecan (TRODELVY), an antibody-drug conjugate developed by Gilead Sciences. The data, shared during a late-breaking presentation at the 2025 San Antonio Breast Cancer Symposium, highlight the safety, pharmacodynamic activity, and

Read More
Representative image illustrating next-generation cancer vaccine research targeting “retired proteins” like alpha-lactalbumin—reflecting the new wave of immunization strategies explored in our story: “Can cancer vaccines finally deliver on their promise?
Features & Analysis

Why are “retired proteins” the hottest new targets in cancer immunotherapy research?

Few ideas have captivated both the scientific imagination and biotech investment flows quite like the cancer vaccine. For decades, the industry narrative was full of hope—and disappointment. The graveyard of failed trials stretches from Dendreon’s Provenge to once-hyped peptide and dendritic cell platforms. For every announcement of an “immune breakthrough,” there seemed to be a

Read More
Pharma & Biotech

Can Actinium’s ATNM-400 radiotherapy reshape treatment for resistant breast cancer?

Actinium Pharmaceuticals, Inc. has presented new preclinical data for its alpha-particle radiotherapy candidate ATNM-400 at the 2025 San Antonio Breast Cancer Symposium (SABCS), highlighting potent anti-tumor activity across hormone receptor–positive, triple-negative, and therapy-resistant breast cancer models. The findings suggest that ATNM-400 could become a differentiated treatment option for patients with tumors that have progressed after

Read More
Pharma & Biotech

Could NanOlogy’s targeted intratumoral cisplatin rewrite the outlook for DIPG in children?

NanOlogy, LLC, a Texas-based clinical-stage oncology company, has announced the launch of a drug development program focused on diffuse intrinsic pontine glioma, known as DIPG, a universally fatal pediatric brainstem tumor. The company is advancing Large Surface Area Microparticle Cisplatin, or LSAM-cisplatin, designed for stereotactic intratumoral administration in children. Investigational New Drug–enabling studies are underway,

Read More
Pharma & Biotech

Can Eli Lilly’s Inluriyo outpace rivals in ESR1-mutated breast cancer after EMBER-3?

Eli Lilly and Company has released updated Phase 3 EMBER-3 results for Inluriyo, also known as imlunestrant, its oral estrogen receptor antagonist, in patients with estrogen receptor-positive and human epidermal growth factor receptor 2–negative advanced or metastatic breast cancer. These new data, presented at the 2025 San Antonio Breast Cancer Symposium and published in Annals

Read More
Pharma & Biotech

NiKang Therapeutics unveils NKT5097 as dual CDK2/4 degrader for solid tumor strategy

NiKang Therapeutics’ NKT5097 enters Phase 1 as a dual CDK2/4 degrader aiming to overcome breast cancer resistance. Explore what this strategy changes.

Read More